HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice

Cancer Research

Volumn 60, Issue 13, 2000, Pages 3569-3576

  Reilly, R Todd ^a   Gottlieb, Morris B C ^a   Ercolini, Anne M ^a   Machiels, Jean Pascal H ^a   Kane, Colin E ^a   Okoye, Francesca I ^a   Muller, William J ^c   Dixon, Katharine H ^b   Jaffee, Elizabeth M ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c MCMASTER UNIVERSITY   (Canada)

^d Bunting Blaustein Cancer   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; CANCER IMMUNOLOGY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TRANSGENIC ANIMAL; TRANSGENIC MOUSE; TUMOR REJECTION;

3T3 CELLS; ADENOCARCINOMA; ANIMALS; CANCER VACCINES; FEMALE; GENES, ERBB-2; IMMUNE TOLERANCE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; RATS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; THYMUS GLAND;

EID: 0034234934     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Wang, M., Chen, P. W., Bronte, V., Rosenberg, S. A., and Restifo, N. P. Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. J. Immunother. Emphasis Tumor Immunol., 18: 139-146, 1995.
2. Wang, M., Bronte, V., Chen, P. W., Gritz, L., Panicali, D., Rosenberg, S. A., and Restifo, N. P. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol., 154: 4685-4692, 1995.
3. Pan, Z. K., Ikonomidis, G., Lazenby, A., Pardoll, D., and Paterson, Y. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat. Med., 1: 471-477, 1995.
4. Pan, Z. K., Ikonomidis, G., Pardoll, D., and Paterson, Y. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. Cancer Res., 55: 4776-4779, 1995.
5. Schirmbeck, R., Bohm, W., and Reimann, J. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors. J. Immunol., 157: 3550-3558, 1996.
6. Bright, R. K., Shearer, M. H., and Kennedy, R. C. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity. J. Immunol., 153: 2064-2071, 1994.
7. Bright, R. K., Beames, B., Shearer, M. H., and Kennedy, R. C. Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen. Cancer Res., 56: 1126-1130, 1996.
8. Jaffee, E. M., and Pardoll, D. M. Murine tumor antigens: is it worth the search? (Review). Curr. Opin. Immunol., 8: 622-627, 1996.
9. Hellstrom, I., and Hellstrom, K. E. T cell immunity to tumor antigens (Review). Crit. Rev. Immunol., 18: 1-6, 1998.
10. Kawakami, Y., and Rosenberg, S. A. Human tumor antigens recognized by T-cells (Review). Immunol. Res., 16: 313-339, 1997.
11. Van den Eynde, B. J., and van der Bruggen, P. T cell defined tumor antigens (Review). Curr. Opin. Immunol., 9: 684-693, 1997.
12. Van den Eynde, B. J., and Boon, T. Tumor antigens recognized by T lymphocytes (Review). Int. J. Clin. Lab. Res., 27: 81-86, 1997.
13. Clarke, P., Mann, J., Simpson, J. F., Rickard-Dickson, K., and Primus, F. J. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res., 58: 1469-1477, 1998.
14. Kass, E., Schlom, J., Thompson, J., Guadagni, F., Graziano, P., and Greiner, J. W. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res., 59: 676-683, 1999.
15. Thompson, J. A., Eades, P. A., Ditter, M., Muller, W. J., and Zimmermann, W. Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: an animal model for CEA-directed tumor immunotherapy. Int. J. Cancer, 72: 197-202, 1997.
16. Wei, C., Willis, R. A., Tilton, B. R., Looney, R. J., Lord, E. M., Barth, R. K., and Frelinger, J. G. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc. Natl. Acad. Sci. USA, 94: 6369-6374, 1997.
17. Morgan, D. J., Kreuwel, H. T., Fleck, S., Levitsky, H. I., Pardoll, D. M., and Sherman, L. A. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol., 160: 643-651, 1998.
18. Hu, J., Kindsvogel, W., Busby, S., Bailey, M. C., She, Y-y., and Greenberg, P. D. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissue. J. Exp. Med., 177: 1681-1690, 1993.
19. Rowse, G. J., Tempero, R. M., VanLith, M. L., Hollingsworth, M. A., and Gendler, S. J. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res., 58: 315-321, 1998.
20. Heike, M., Blachere, N. E., and Srivastava, P. K. Protective cellular immunity against a spontaneous mammary carcinoma from ras transgenic mice. Immunobiology, 190: 411-423, 1994.
21. Gingrich, J. R., Barrios, R. J., Kattan, M. W., Nahm, H. S., Finegold, M. J., and Greenberg, N. M. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res., 57: 4687-4691, 1997.
22. Greenberg, N. M., DeMayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A. A., Matusik, R. J., and Rosen, J. M. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA, 92: 3439-3443, 1995.
23. Disis, M. L., Calenoff, E., McLaughlin, G., Murphy, A. E., Chen, W., Groner, B., Jeschke, M., Lydon, N., McGlynn, E., Livingston, R. B., et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res., 54: 16-20, 1994.
24. Disis, M. L., Pupa, S. M., Gralow, J. R., Dittadi, R., Menard, S., and Cheever, M. A. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin. Oncol., 15: 3363-3367, 1997.
25. Fisk, B., Blevins, T. L., Wharton, J. T., and Ioannides, C. G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med., 181: 2109-2117, 1995.
26. Ioannides, C. G., Fisk, B., Fan, D., Biddison, W. E., Wharton, J. T., and O'Brian, C. A. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell. Immunol., 151: 225-234, 1993.
27. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA, 92: 432-436, 1995.
28. Yoshino, I., Goedegebuure, P. S., Peoples, G. E., Parikh, A. S., DiMaio, J. M., Lyerly, H. K., Gazdar, A. F., and Eberlein, T. J. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res., 54: 3387-3390, 1994.
29. Disis, M. L., Grabstein, K. H., Sleath, P. R., and Cheever, M. A. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res., 5: 1289-1297, 1999.
30. Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., and Muller, W. J. Expression of the neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA, 89: 10578-82, 1992.
31. Guy, C. T., Cardiff, R. D., and Muller, W. J. Activated neu induces rapid tumor progression. J. Biol. Chem., 271: 7673-7678, 1996.
32. Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., and Leder, P. Single-step induction of mammary adenocarcinoma in transgenic mice hearing the activated C-Neu oncogene. Cell, 54: 105-115, 1988.
33. Amici, A., Venanzi, F. M., and Concetti, A. Genetic immunization against neu/erbB2 transgenic breast cancer. Cancer Immunol. Immunother., 47: 183-190, 1998.
34. Cefai, D., Morrison, B. W., Sckell, A., Favre, L., Balli, M., Leunig, M., and Gimmi, C. D. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer. Int. J. Cancer, 83: 393-400, 1999.
35. Cardiff, R. D., and Muller, W. J. Transgenic mouse models of mammary tumorigenesis (Review). Cancer Surv., 16: 97-113, 1993.
36. Muller, W. J. Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer. Cancer Metastasis Rev., 10: 217-227, 1991.
37. Jaffee, E. M., Schutte, M., Gossett, J., Morsberger, L. A., Adler, A. J., Thomas, M., Greten, T. F., Hruban, R. H., Yeo, C. J., and Griffin, C. A. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am., 4: 194-203, 1998.
38. Drebin, J. A., Link, V. C., Weinberg, R. A., and Greene, M. I. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc. Natl. Acad. Sci. USA. 83: 9129-9133, 1986.
39. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
40. Jaffee, E. M., Dranoff, G., Cohen, L. K., Hauda, K. M., Clift, S., Marshall, F. F., Mulligan, R. C., and Pardoll, D. M. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res., 53: 2221-2226, 1993.
41. Adler, A. J., Marsh, D. W., Yochum, G. S., Guzzo, J. L., Nigam, A., Nelson, W. G., and Pardoll, D. M. CD4+ T cell tolerance to parenchymal self-antigens requires presentation by hone marrow-derived antigen-presenting cells. J. Exp. Med., 187: 1555-1564, 1998.
42. Coligan, J. E. (ed.). Current Protocols on CD-ROM, 1999 edition. New York: John Wiley and Sons, Inc., 1999.
43. Bernards, R., Destree, A., McKenzie, S., Gordon, E., Weinberg, R. A., and Panicali, D. Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc. Natl. Acad. Sci. USA, 84: 6854-6858, 1987.
44. Chen, Y., Hu, D., Eling, D. J., Robbins, J., and Kipps, T. J. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res., 58: 1965-1971, 1998.
45. Liu, G. Y., Fairchild, P. J., Smith, R. M., Prowle, J. R., Kioussis, D., and Wraith, D. C. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity. 3: 407-415, 1995.
46. Katsumata, M., Okudaira, T., Samanta, A., Clark, D. P., Drebin, J. A., Jolicoeur, P., and Greene, M. I. Prevention of breast tumour development in vivo by down-regulation of the p185neu receptor (see comments). Nat. Med., 1: 644-648, 1995.
47. Esserman, L. J., Lopez, T., Montes, R., Bald, L. N., Fendly, B. M., and Campbell, M. J. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol. Immunother., 47: 337-342, 1999.